Evaluation of the frequency of mutation genes in multidrug-resistant tuberculosis (MDR-TB) strains in Beijing, China.
Adolescent
Adult
Aged
Aged, 80 and over
Antitubercular Agents
/ pharmacology
Bacterial Proteins
/ genetics
Beijing
/ epidemiology
Catalase
/ genetics
Drug Resistance, Multiple, Bacterial
Female
Genotype
Humans
Male
Middle Aged
Mutation
Mycobacterium tuberculosis
/ drug effects
Oxidoreductases
/ genetics
Tuberculosis, Multidrug-Resistant
/ epidemiology
Young Adult
Beijing genotype
Mycobacterium tuberculosis
isoniazid
multidrug-resistant tuberculosis (MDR-TB)
rifampin
Journal
Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737
Informations de publication
Date de publication:
05 01 2021
05 01 2021
Historique:
pubmed:
6
1
2021
medline:
21
4
2021
entrez:
5
1
2021
Statut:
epublish
Résumé
The aim of this study was to explore the frequency and distribution of gene mutations that are related to isoniazid (INH) and rifampin (RIF)-resistance in the strains of the multidrug-resistant tuberculosis (MDR-TB) Mycobacterium tuberculosis (M.tb) in Beijing, China. In this retrospective study, the genotypes of 173 MDR-TB strains were analysed by spoligotyping. The katG, inhA genes and the promoter region of inhA, in which genetic mutations confer INH resistance; and the rpoB gene, in which genetic mutations confer RIF resistance, were sequenced. The percentage of resistance-associated nucleotide alterations among the strains of different genotypes was also analysed. In total, 90.8% (157/173) of the MDR strains belonged to the Beijing genotype. Population characteristics were not significantly different among the strains of different genotypes. In total, 50.3% (87/173) strains had mutations at codon S315T of katG; 16.8% (29/173) of strains had mutations in the inhA promoter region; of them, 5.5% (15/173) had point mutations at -15 base (C→T) of the inhA promoter region. In total, 86.7% (150/173) strains had mutations at rpoB gene; of them, 40% (69/173) strains had mutations at codon S531L of rpoB. The frequency of mutations was not significantly higher in Beijing genotypic MDR strains than in non-Beijing genotypes. Beijing genotypic MDR-TB strains were spreading in Beijing and present a major challenge to TB control in this region. A high prevalence of katG Ser315Thr, inhA promoter region (-15C→T) and rpoB (S531L) mutations was observed. Molecular diagnostics based on gene mutations was a useful method for rapid detection of MDR-TB in Beijing, China.
Identifiants
pubmed: 33397543
doi: 10.1017/S0950268820003131
pii: S0950268820003131
pmc: PMC8057498
doi:
Substances chimiques
Antitubercular Agents
0
Bacterial Proteins
0
Oxidoreductases
EC 1.-
Catalase
EC 1.11.1.6
katG protein, Mycobacterium tuberculosis
EC 1.11.1.6
InhA protein, Mycobacterium
EC 1.3.1.9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e21Références
FEMS Microbiol Rev. 2017 May 1;41(3):354-373
pubmed: 28369307
BMC Genomics. 2019 Mar 29;20(1):252
pubmed: 30922221
Microb Pathog. 2018 Apr;117:237-242
pubmed: 29486274
Antimicrob Agents Chemother. 2014;58(4):1997-2005
pubmed: 24419342
N Engl J Med. 2012 Jun 7;366(23):2161-70
pubmed: 22670902
Microbiol Spectr. 2014 Aug;2(4):MGM2-0014-2013
pubmed: 26104204
Epidemiol Infect. 2015 Jan;143(1):141-9
pubmed: 24667051
J Clin Microbiol. 2012 Jul;50(7):2404-13
pubmed: 22553245
J Antimicrob Chemother. 2011 Jul;66(7):1417-30
pubmed: 21558086
Antimicrob Agents Chemother. 2006 Aug;50(8):2640-9
pubmed: 16870753
Lancet Infect Dis. 2018 Dec;18(12):1350-1359
pubmed: 30342828
PLoS One. 2017 Mar 23;12(3):e0174197
pubmed: 28333978
BMC Infect Dis. 2018 Dec 14;18(1):658
pubmed: 30547765
Tuberculosis (Edinb). 2013 Jan;93(1):84-8
pubmed: 23146281
Clin Microbiol Infect. 2007 Jun;13(6):620-6
pubmed: 17403134
Antimicrob Agents Chemother. 2005 Mar;49(3):1229-31
pubmed: 15728936
BMC Infect Dis. 2018 Dec 29;18(1):710
pubmed: 30594126
Int J Tuberc Lung Dis. 2015 Nov;19(11):1276-89
pubmed: 26467578
J Clin Microbiol. 2003 Sep;41(9):4471-4
pubmed: 12958298
Antimicrob Agents Chemother. 2002 May;46(5):1417-24
pubmed: 11959577
Int J Infect Dis. 2018 Nov;76:109-119
pubmed: 29936318
PLoS One. 2014 Sep 19;9(9):e106787
pubmed: 25237849
Tuberculosis (Edinb). 2014 Mar;94(2):159-61
pubmed: 24325872
J Glob Antimicrob Resist. 2016 Jun;5:92-3
pubmed: 27436477
Antimicrob Agents Chemother. 2010 Mar;54(3):1075-81
pubmed: 20008778
J Antimicrob Chemother. 2007 Jun;59(6):1057-64
pubmed: 17442757
J Infect. 2015 Apr;70(4):335-45
pubmed: 25485999
Nature. 1992 Aug 13;358(6387):591-3
pubmed: 1501713
J Clin Microbiol. 2012 Mar;50(3):598-601
pubmed: 22170905
J Antibiot (Tokyo). 2014 Apr;67(4):291-7
pubmed: 24326341
Indian J Med Microbiol. 2015 Feb;33 Suppl:46-52
pubmed: 25657156
Antimicrob Agents Chemother. 2014 Jun;58(6):3475-80
pubmed: 24733464
Int J Infect Dis. 2009 Nov;13(6):673-8
pubmed: 19138546
Int J Tuberc Lung Dis. 2011 Jun;15(6):789-94
pubmed: 21575300